Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine.
Cerebrospinal fluid (CSF) S-adenosylmethionine (SAM) levels were significantly lower in severely depressed patients than in a neurological control group. The administration of SAM either intravenously or orally is associated with a significant rise of CSF SAM, indicating that it crosses the blood-brain barrier in humans. These observations provide a rational basis for the antidepressant effect of SAM, which has been confirmed in several countries. CSF SAM levels were low in a group of patients with Alzheimer's dementia suggesting a possible disturbance of methylation in such patients and the need for trials of SAM treatment.
Bottiglieri
T
T
Department of Neurology, King's College Hospital, London, United Kingdom.
Godfrey
P
P
Flynn
T
T
Carney
M W
MW
Toone
B K
BK
Reynolds
E H
EH
D000284:Administration, Oral; D000328:Adult; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D001812:Blood-Brain Barrier; D003866:Depressive Disorder / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D012436:S-Adenosylmethionine / Q000008:administration & dosage / Q000134:cerebrospinal fluid* / Q000627:therapeutic use
D012436:S-Adenosylmethionine